Cagrilintide

Cagrilintide is a long-acting amylin analogue that regulates appetite, slows gastric emptying, and improves glucose control, making it effective for weight loss and glycemic management. When combined with GLP-1 receptor agonists like semaglutide, it enhances metabolic outcomes and supports sustained weight reduction. Cagrilintide is a synthetic, long-acting amylin analogue developed to enhance metabolic health and support weight management. It is structurally similar to natural amylin but includes key modifications, such as lipidation of the N-terminal lysine and specific amino acid substitutions (N14E, V17R, and P37Y), which improve stability and therapeutic efficacy. By activating amylin receptors and modulating hunger and energy expenditure, Cagrilintide has shown promise in obesity management and glycemic control, particularly when combined with GLP-1 receptor agonists like semaglutide.

- Support weight loss and appetite control by enhancing satiety and reducing food intake

- Regulate blood sugar levels and improve metabolic health

Mechanism of Action

How this peptide works in the body

Appetite Regulation:

Cagrilintide activates amylin receptors (AMYRs) in the area postrema and nucleus of the solitary tract (NTS) of the brainstem, reducing hunger and increasing satiety. This activation modulates neuropeptide signaling, including suppression of neuropeptide Y (NPY) (which promotes hunger) and stimulation of pro-opiomelanocortin (POMC)(which enhances satiety), leading to a sustained decrease in food intake.

Gastric Emptying Delay:

By modulating vagal nerve activity, Cagrilintide reduces gastrointestinal motility and slows gastric emptying, prolonging the sensation of fullness after meals. This occurs through amylin receptor activation in the dorsal vagal complex (DVC), which decreases cholinergic signaling to the stomach, resulting in delayed gastric emptying and prolonged nutrient absorption.

Glucose Control:

Cagrilintide enhances postprandial glucose regulation by suppressing glucagon secretion from pancreatic alpha cells, reducing hepatic glucose production. This leads to improved insulin sensitivity and more stable blood sugar levels, particularly in individuals with type 2 diabetes or insulin resistance.

Combination Benefits:

When used with GLP-1 receptor agonists like semaglutide, Cagrilintide amplifies weight loss and metabolic benefits by targeting complementary pathways. GLP-1 enhances insulin secretion and beta-cell function, while amylin receptor activation reduces appetite and delays gastric emptying, creating a synergistic effect for superior metabolic outcomes.